Risk of arterial thrombosis not increased by sorafenib or sunitinib.
Minor
David R
DR
D020533:Angiogenesis Inhibitors / Q000009:adverse effects*; D001157:Arterial Occlusive Diseases / Q000139:chemically induced*; D001557:Benzenesulfonates / Q000009:adverse effects*; D019317:Evidence-Based Medicine; D006801:Humans; D007211:Indoles / Q000009:adverse effects*; D009536:Niacinamide / Q000031:analogs & derivatives; D010671:Phenylurea Compounds; D047428:Protein Kinase Inhibitors / Q000009:adverse effects*; D011725:Pyridines / Q000009:adverse effects*; D011758:Pyrroles / Q000009:adverse effects*; D015203:Reproducibility of Results; D018570:Risk Assessment; D012307:Risk Factors; D000077157:Sorafenib; D000077210:Sunitinib; D013923:Thromboembolism / Q000139:chemically induced*
D020533:Angiogenesis Inhibitors; D001557:Benzenesulfonates; D007211:Indoles; D010671:Phenylurea Compounds; D047428:Protein Kinase Inhibitors; D011725:Pyridines; D011758:Pyrroles; D009536:Niacinamide; D000077157:Sorafenib; D000077210:Sunitinib